Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figuring out the Justification for Separation: To blame and No-Shortcoming - 2Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- 3Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- 4Millions in JDM Exports and Exotic Supercars Are Currently Trapped at Sea
- 5The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- Smooth out Your Funds: Cash The board Simplified
- Windows to the Previous: An Excursion Through the World's Notable Engineering
- Israeli president concerned over proposed renaming of park
- Pick Your #1 Japanese Food
- Jill Hennessy was a '90s TV staple. Now she's in her fearless era.
- A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- Vote In favor of Your Favored Kind Of Vegetable
- 5 Fundamental Ways to employ a Criminal Legal counselor
